Erratum. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90-97.

To comply with a new (January 2020) legal interpretation of the Data Use Agreement between the U.S. Food and Drug Administration’s Sentinel Initiative and the Centers for Medicare & Medicaid Services, the authors have made changes to the presentation of data in this article and the online supplementary material …